메뉴 건너뛰기




Volumn 30, Issue 12, 2013, Pages 1128-1140

The INITIATOR study: Pilot data on real-world clinical and economic outcomes in us patients with type 2 diabetes initiating injectable therapy

Author keywords

Health care costs; Injectable treatment; Treatment initiation; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLARGINE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; LONG ACTING INSULIN;

EID: 84890551197     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0074-8     Document Type: Article
Times cited : (20)

References (22)
  • 1
    • 84866268783 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes: A patient-centered approach
    • 1:CAS:528:DC%2BC38Xps1Kitb4%3D 3357214 22517736 10.2337/dc12-0413
    • Inzucchi SE, Nauck M, Bergenstal RM, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012;35:1364-79.
    • (2012) Diabetes Care , vol.35 , pp. 1364-1379
    • Inzucchi, S.E.1    Nauck, M.2    Bergenstal, R.M.3
  • 2
    • 33644798145 scopus 로고    scopus 로고
    • Resistance to insulin therapy among patients and providers: Results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study
    • 16249538 10.2337/diacare.28.11.2673
    • Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care. 2005;28:2673-9.
    • (2005) Diabetes Care , vol.28 , pp. 2673-2679
    • Peyrot, M.1    Rubin, R.R.2    Lauritzen, T.3
  • 3
    • 77953044294 scopus 로고    scopus 로고
    • Barriers to insulin initiation: The translating research into action for diabetes insulin starts project
    • 2845015 20086256 10.2337/dc09-1184
    • Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010;33:733-5.
    • (2010) Diabetes Care , vol.33 , pp. 733-735
    • Karter, A.J.1    Subramanian, U.2    Saha, C.3
  • 5
    • 84862653963 scopus 로고    scopus 로고
    • What can we learn from patient-reported outcomes of insulin pen devices?
    • 3262728 22226279
    • Anderson BJ, Redondo MJ. What can we learn from patient-reported outcomes of insulin pen devices? J Diabetes Sci Technol. 2011;5:1563-71.
    • (2011) J Diabetes Sci Technol. , vol.5 , pp. 1563-1571
    • Anderson, B.J.1    Redondo, M.J.2
  • 6
    • 50149104154 scopus 로고    scopus 로고
    • Physician perception and recommendation of insulin pens for patients with type 2 diabetes mellitus
    • 18627641 10.1185/03007990802278644
    • Peyrot M, Rubin RR. Physician perception and recommendation of insulin pens for patients with type 2 diabetes mellitus. Curr Med Res Opin. 2008;24:2413-22.
    • (2008) Curr Med Res Opin. , vol.24 , pp. 2413-2422
    • Peyrot, M.1    Rubin, R.R.2
  • 7
    • 77956139699 scopus 로고    scopus 로고
    • Health economics and compliance of vials/syringes versus pen devices: A review of the evidence
    • 20515297
    • Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther. 2010;12:S101-8.
    • (2010) Diabetes Technol Ther , vol.12
    • Asche, C.V.1    Shane-Mcwhorter, L.2    Raparla, S.3
  • 8
    • 33751566656 scopus 로고    scopus 로고
    • Medication adherence and the associated health economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third party managed care claims data
    • 17157128 10.1016/j.clinthera.2006.10.004
    • Lee W, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third party managed care claims data. Clin Ther. 2006;28:1712-23.
    • (2006) Clin Ther , vol.28 , pp. 1712-1723
    • Lee, W.1    Balu, S.2    Cobden, D.3    Joshi, A.V.4    Pashos, C.L.5
  • 9
    • 38449113522 scopus 로고    scopus 로고
    • Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: A retrospective database analysis
    • 10.1016/j.clinthera.2007.07.007
    • Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007;29:1294-305.
    • (2007) Clin Ther. , vol.29 , pp. 1294-1305
    • Pawaskar, M.D.1    Camacho, F.T.2    Anderson, R.T.3    Cobden, D.4    Joshi, A.V.5    Balkrishnan, R.6
  • 10
    • 69949117621 scopus 로고    scopus 로고
    • Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): A randomised controlled trial
    • 1:CAS:528:DC%2BD1MXhtVygtLnE 2744824 19688338 10.1007/s00125-009-1472-y
    • Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52:2046-55.
    • (2009) Diabetologia. , vol.52 , pp. 2046-2055
    • Russell-Jones, D.1    Vaag, A.2    Schmitz, O.3
  • 12
    • 33745814404 scopus 로고    scopus 로고
    • Are claims data accurate enough to identify patients for performance measures or quality improvement? the case of diabetes, heart disease, and depression
    • 16849780 10.1177/1062860606288243
    • Solberg LI, Engebretson KI, Sperl-Hillen JM, Hroscikoski MC, O'Connor PJ. Are claims data accurate enough to identify patients for performance measures or quality improvement? The case of diabetes, heart disease, and depression. Am J Med Qual. 2006;21:238-45.
    • (2006) Am J Med Qual. , vol.21 , pp. 238-245
    • Solberg, L.I.1    Engebretson, K.I.2    Sperl-Hillen, J.M.3    Hroscikoski, M.C.4    O'Connor, P.J.5
  • 13
    • 77955096791 scopus 로고    scopus 로고
    • Validating ICD coding algorithms for diabetes mellitus from administrative data
    • 20363043 10.1016/j.diabres.2010.03.007
    • Chen G, Khan N, Walker R, Quan H. Validating ICD coding algorithms for diabetes mellitus from administrative data. Diabetes Res Clin Pract. 2010;89:189-95.
    • (2010) Diabetes Res Clin Pract. , vol.89 , pp. 189-195
    • Chen, G.1    Khan, N.2    Walker, R.3    Quan, H.4
  • 14
    • 27744568384 scopus 로고    scopus 로고
    • Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
    • 16224307 10.1097/01.mlr.0000182534.19832.83
    • Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-9.
    • (2005) Med Care. , vol.43 , pp. 1130-1139
    • Quan, H.1    Sundararajan, V.2    Halfon, P.3
  • 15
    • 84890549431 scopus 로고    scopus 로고
    • US Department of Labor, Bureau of Labor Statistics. Consumer Price Index Series ID: SUUR0000SAM. Washington, DC: U.S. Dept. of Labor, Bureau of Labor Statistics Last accessed August 28, 2013
    • US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Chained Consumer Price Index for all urban consumers (C-CPI-U) 1999-2008, Medical Care. Series ID: SUUR0000SAM. Washington, DC: U.S. Dept. of Labor, Bureau of Labor Statistics, 2008. http://data.bls.gov/cgi-bin/surveymost?su. Last accessed August 28, 2013.
    • (2008) Chained Consumer Price Index for All Urban Consumers (C-CPI-U) 1999-2008, Medical Care
  • 16
    • 81255124243 scopus 로고    scopus 로고
    • Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID
    • 21892858 10.3111/13696998.2011.605818
    • Baser O, Wei W, Baser E, Xie L. Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID. J Med Econ. 2011;14:673-80.
    • (2011) J Med Econ. , vol.14 , pp. 673-680
    • Baser, O.1    Wei, W.2    Baser, E.3    Xie, L.4
  • 17
    • 82355180949 scopus 로고    scopus 로고
    • A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens
    • 1:CAS:528:DC%2BC3MXhsVyrtL%2FE 22038703 10.1007/s12325-011-0074-5
    • Xie L, Wei W, Pan C, Du J, Baser O. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens. Adv Ther. 2011;28:1000-11.
    • (2011) Adv Ther. , vol.28 , pp. 1000-1011
    • Xie, L.1    Wei, W.2    Pan, C.3    Du, J.4    Baser, O.5
  • 18
    • 84875205714 scopus 로고    scopus 로고
    • Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus
    • 1:CAS:528:DC%2BC3sXktV2rtbw%3D 23336845 10.1089/dia.2012.0253
    • Xie L, Zhou S, Wei W, Gill J, Pan C, Baser O. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2013;15:230-6.
    • (2013) Diabetes Technol Ther. , vol.15 , pp. 230-236
    • Xie, L.1    Zhou, S.2    Wei, W.3    Gill, J.4    Pan, C.5    Baser, O.6
  • 19
    • 84855846339 scopus 로고    scopus 로고
    • Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting
    • 21550952 10.4158/EP10401.OR
    • Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract. 2011;17:845-52.
    • (2011) Endocr Pract. , vol.17 , pp. 845-852
    • Davis, S.N.1    Wei, W.2    Garg, S.3
  • 20
    • 84862108594 scopus 로고    scopus 로고
    • Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes
    • 3329848 22432106 10.2337/dc11-2048
    • Zhao Y, Campbell CR, Fonseca V, Shi L. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care. 2012;35:1126-32.
    • (2012) Diabetes Care. , vol.35 , pp. 1126-1132
    • Zhao, Y.1    Campbell, C.R.2    Fonseca, V.3    Shi, L.4
  • 21
    • 83655184782 scopus 로고    scopus 로고
    • Achieving a clinically relevant composite outcome of an HbA1c of < 7% without weight gain or hypoglycaemia in type 2 diabetes: A meta-analysis of the liraglutide clinical trial programme
    • 1:CAS:528:DC%2BC38XhvFOmsb4%3D 21883806 10.1111/j.1463-1326.2011.01493.x
    • Zinman B, Schmidt WE, Moses A, Lund N, Gough S. Achieving a clinically relevant composite outcome of an HbA1c of < 7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab. 2012;14:77-82.
    • (2012) Diabetes Obes Metab. , vol.14 , pp. 77-82
    • Zinman, B.1    Schmidt, W.E.2    Moses, A.3    Lund, N.4    Gough, S.5
  • 22
    • 84862207266 scopus 로고    scopus 로고
    • Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    • 1:CAS:528:DC%2BC38Xos1Wkurs%3D 10.1038/ijo.2011.158
    • Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36:843-54.
    • (2012) Int J Obes. , vol.36 , pp. 843-854
    • Astrup, A.1    Carraro, R.2    Finer, N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.